Autoimmune Encephalitis Clinical Trial
Official title:
Clinical Features and Prognostic Markers in Adult Patients With AE Requiring ICU Treatment
Autoimmune encephalitis (AE) is a potentially life-threatening inflammation of the central nervous system (CNS) and constitutes 20%-30% of encephalitis cases in adults AE often leads to subacute, severe, and debilitating encephalitis necessitating long-term management in a neurologic intensive care unit (ICU). This study aims to explore the predictive factors for poor clinical outcomes by analyzing the clinical characteristics and prognosis of adult patients with critical AE requiring ICU admission. Prospective observational single center study in neurologic ICU, the second Xiangya hospital, Central South University. All patients admitted to the ICU for probable or confirmed AE (2022 Chinese guidelines for diagnosis and treatment of AE) will be included. Factors associated with a poor prognosis will be identified by multivariate analysis using a logistic regression.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
| Completed |
NCT05645185 -
Characterisation of Clinical Phenotypes and Outcomes of Ma2 Patient
|
||
| Not yet recruiting |
NCT04106596 -
HLA Analysis in Autoimmune Encephalitis and Related Disorders
|
||
| Completed |
NCT04708626 -
Epidemiology of Autoimmune Encephalitides and Paraneoplastic Neurological Syndromes in Sweden
|
||
| Not yet recruiting |
NCT05711563 -
Predicting and Monitoring Outcomes in Autoimmune Encephalitis
|
||
| Completed |
NCT04175522 -
Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis:
|
Phase 2 | |
| Recruiting |
NCT03194815 -
IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2
|
Phase 2 | |
| Recruiting |
NCT06079294 -
Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
|
N/A | |
| Not yet recruiting |
NCT03957616 -
Incidence of Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis
|
||
| Completed |
NCT02905136 -
Mechanisms of Auto-immune Encephalitis
|
||
| Recruiting |
NCT05280600 -
Developing Advanced Neuroimaging for Clinical Evaluation of Autoimmune Encephalitis
|
||
| Recruiting |
NCT06173076 -
A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis
|
||
| Recruiting |
NCT03993262 -
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
|
Phase 2 | |
| Recruiting |
NCT06033846 -
Efficacy and Safety of Adjunctive Minocycline in the Treatment of Autoimmune Encephalitis
|
Phase 2 | |
| Recruiting |
NCT04372615 -
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
|
Phase 2 | |
| Recruiting |
NCT05177939 -
Phase III Clinical Study of NPB-01 in Patients With Autoimmune Encephalitis
|
Phase 3 | |
| Active, not recruiting |
NCT06432803 -
Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS
|
||
| Recruiting |
NCT06019975 -
FDG-PET in the Diagnosis of Autoimmune Encephalitis
|
||
| Completed |
NCT05783947 -
Diagnostic Performance of a Commercial Assay for the Detection of Neuronal Antibodies
|
||
| Completed |
NCT05825690 -
BRIEF TITLE * (in English and Sufficiently Descriptive) Role of MRI in Anti-LGI1 Encephalitis
|